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Friedreich ataxia (FRDA) is a neurodegenerative disorder caused by an unstable GAA repeat expansion mutation within intron 1 of the FXN
gene. However, the origins of the GAA repeat expansion, its unstable dynamics within different cells and tissues, and its effects on frataxin
expression are not yet completely understood. Therefore, we have chosen to generate representative FRDA mouse models by using the human
FXN GAA repeat expansion itself as the genetically modified mutation. We have previously reported the establishment of two lines of human
FXN YAC transgenic mice that contain unstable GAA repeat expansions within the appropriate genomic context. We now describe the
generation of FRDA mouse models by crossbreeding of both lines of human FXN YAC transgenic mice with heterozygous Fxn knockout mice.
The resultant FRDA mice that express only human-derived frataxin show comparatively reduced levels of frataxin mRNA and protein expression,
decreased aconitase activity, and oxidative stress, leading to progressive neurodegenerative and cardiac pathological phenotypes. Coordination
deficits are present, as measured by accelerating rotarod analysis, together with a progressive decrease in locomotor activity and increase in
weight. Large vacuoles are detected within neurons of the dorsal root ganglia (DRG), predominantly within the lumbar regions in 6-month-old
mice, but spreading to the cervical regions after 1 year of age. Secondary demyelination of large axons is also detected within the lumbar roots of
older mice. Lipofuscin deposition is increased in both DRG neurons and cardiomyocytes, and iron deposition is detected in cardiomyocytes after 1
year of age. These mice represent the first GAA repeat expansion-based FRDA mouse models that exhibit progressive FRDA-like pathology and
thus will be of use in testing potential therapeutic strategies, particularly GAA repeat-based strategies.
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neurodegenerative disorder that is predominantly caused by a
homozygous GAA repeat expansion mutation within intron 1 of
the FXN gene (formerly FRDA) [1]. Normal individuals have 5
to 30 GAA repeat sequences, whereas affected individuals have
from approximately 70 to more than 1000 GAA triplets [2]. The
effect of the GAA expansion mutation is to reduce greatly the⁎ Corresponding author. Fax: +44 1895 274348.
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doi:10.1016/j.ygeno.2006.06.015expression of frataxin [3], a mitochondrial protein that interacts
with succinate dehydrogenase complex subunits [4] and acts
both as an iron chaperone in iron–sulfur clusters and heme
biosynthesis [5–8] and as an iron detoxifier [9]. A direct
correlation has been identified between the size of the smaller of
the two GAA repeat mutations (and hence the level of residual
frataxin expression) and the age of onset and severity of FRDA
disease phenotype [3,10–12]. Evidence suggests that the GAA
repeat expansion may have its effect by adopting an abnormal
triplex structure that interferes with FXN gene transcription
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that sequesters transcription factors [15]. It has also been
suggested that GAA repeats may produce a heterochromatin-
mediated gene silencing effect [16].
The generation of a representative mouse model of FRDA is
considered important for the further understanding of disease
pathology and the testing of potential therapeutic strategies.
Thus far, strategies have been based on various gene-targeting
approaches to modify the homologous mouse Fxn gene.
Initially, Fxn knockout mice were shown to be embryonic
lethal in the homozygous state [17]. Several Cre/loxP condi-
tional knockout mice have subsequently been generated. These
have each been shown to reproduce some pathological features
of FRDA, including dysfunction of large sensory neurons,
cardiodegeneration, diabetes, deficiency of Fe–S-containing
enzymes, oxidative stress, and mitochondrial iron accumulation
[18–21]. Despite these successes, conditional knockout models
are by their nature selective in the tissues that contain loss or
decreased levels of frataxin and they do not address the question
of GAA repeat mutation dynamics. A different gene-targeting
approach is to introduce a GAA repeat mutation into the mouse
Fxn locus. However, this GAA repeat knock-in strategy is
somewhat hampered by the fact that the Fxn intron 1 region of
the mouse does not normally contain a GAA repeat sequence.
Indeed, knock-in of a 230-GAA repeat sequence into the Fxn
intron 1 has not reproduced triplet repeat instability in mice,
although it did result in decreased frataxin production [22].
We hypothesized that a human genomic FXN transgene that
contained a GAA repeat expansion at the correct intronic
position would enable both GAA repeat instability and reduced
frataxin expression to be obtained within the one single model.
Our previous work demonstrated that a wild-type FXN YAC
transgene could successfully rescue the embryonic lethal
phenotype of the Fxn knockout mouse [17], indicating that
the YAC contained the necessary regulatory elements for
appropriate human frataxin expression in a frataxin null mouse
[23]. We have subsequently generated two lines of human FXN
YAC transgenic mice containing GAA repeat expansions
derived from FRDA patient DNA that exhibit intergenerational
and somatic instability of the GAA repeat [24]. We now
describe the generation of GAA repeat expansion-based FRDA
mouse models by crossbreeding of these FXN YAC transgenic
mice with heterozygous Fxn knockout mice. Offspring are
produced that express comparatively reduced levels of human-
derived frataxin and rescue the homozygous Fxn knockout
embryonic lethality. We detect FRDA-like biochemical, histo-
pathological, and functional losses that will allow these mouse
models to be used for testing effective FRDA therapeutic
strategies.
Results
Human GAA expansion-containing FXN YAC transgenes
rescue FRDA knockout embryonic lethality
Two lines of human FXN YAC transgenic mice that contain
GAA repeat expansions of approximately 190 repeats or 190+90 repeats, designated YG22 and YG8, respectively, have
previously been described [24]. To determine the viability of
each GAA FXN transgene, we set up crosses between YG22 or
YG8 mice (FXN+, Fxn+/+) and heterozygous Fxn knockout
mice (Fxn+/−) [17]. The FXN+, Fxn+/− offspring from these
crosses were further bred with Fxn+/− mice to generate FXN+,
Fxn−/− “rescues.” Correct Mendelian ratios of rescue mice to
overall offspring number were obtained from both YG22 and
YG8 crosses (p>0.25 in each case), indicating functional
frataxin derived from both GAA repeat-containing transgenes.
The rescue mice from both lines exhibit a normal life span, with
mice surviving up to at least 2 years of age.
Decreases in frataxin mRNA and protein expression
To determine the levels of frataxin mRNA expression in
YG22 and YG8 rescue and transgenic mice we performed
semiquantitative RT-PCR using primers that recognize both
human and mouse frataxin cDNA, followed by digestion with
human-specific and mouse-specific restriction enzymes. The
DNA products were standardized by comparison with mouse
Hprt RT-PCR controls and were then determined as a
percentage of wild-type mouse values. The results confirmed
the presence of human-only frataxin mRNA transcripts in both
YG22 and YG8 rescue mice (Fig. 1A). The levels of transgenic
FXN mRNA expression compared to endogenous mouse Fxn
mRNA revealed decreases in all YG22 and YG8 rescue mouse
tissues (Fig. 1B). The greatest, and statistically significant,
decreases were detected in the cerebellum of both YG22 (62%)
and YG8 (57%) rescues, together with the skeletal muscle of
YG8 rescues (57%). This contrasted with YG22 and YG8
transgenic mouse samples, which all showed increases (101 to
145%) in overall frataxin mRNA expression, with approxi-
mately equal contributions from transgenic and endogenous
frataxin mRNA.
To determine the levels of human frataxin expression in
YG22 and YG8 rescue mice we used an anti-human recom-
binant mature frataxin antibody (α-hmfxn) in Western blot
analysis of several different tissue lysates. Our initial analysis of
equalized unaffected human and wild-type mouse skeletal
muscle samples indicated that the α-hmfxn antibody reacts
strongly with human frataxin to give a band of 18 kDa, but
reacts only weakly with mouse frataxin to give a slightly larger
band of 19 kDa (Fig. 2A). We determined the ratio of human to
mouse signal intensities to be 2.3:1. Thus, although a direct
comparison between the human frataxin levels in the YG22 and
YG8 rescue mice and wild-type mouse frataxin levels was not
possible, we were able to calculate the comparative levels of
human frataxin indirectly. Analysis of our results (Fig. 2B–2D)
revealed comparative frataxin levels of 67 and 86% in the
cerebellum, 45 and 52% in the heart, and 23 and 23% in the
skeletal muscle of YG22 and YG8 rescue mice, respectively,
when standardized to an anti-porin mitochondrial antibody
control (p<0.01 for all, except YG8 cerebellum, which was not
significant). These frataxin expression levels were further
decreased to 67 and 42% in cerebellum, 37 and 25% in heart,
and 10 and 9% in skeletal muscle of YG22 and YG8 rescue
Fig. 1. mRNA expression analysis. (A) A representative RT-PCR image showing restriction-digested human frataxin products (112 and 29 bp) and mouse frataxin
products (75 and 64 bp), together with mouseHprt controls. mRNA samples were isolated from tissues of wild-type, YG22 rescue, YG8 rescue, YG22 transgenic, and
YG8 transgenic mice (lanes 1, cerebrum; 2, brain stem; 3, cerebellum; 4, heart; 5, skeletal muscle). (B) Levels of frataxin mRNA expression as a percentage value of
wild-type mouse expression. Values were generated by determining the means of six different RT-PCR experiments, each normalized toHprt. Error bars indicate SEM.
*p<0.05, **p<0.01.
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control (p<0.01 for all). This suggests that there is both a
decrease in the relative amount of frataxin within the
mitochondria and an overall decrease in mitochondria within
the cells of these tissues, especially within the YG8 cerebellar
and heart tissues compared with the corresponding YG22
tissues. Some confirmation of this latter point comes from our
finding of variably decreased (60–90%) levels of porin in all
YG22 and YG8 cerebellum, heart, and skeletal muscle tissues,
compared with wild-type controls (data not shown). In contrast,
the levels of frataxin in the cerebrum and brain stem from both
YG22 and YG8 rescue mice are not similarly reduced, but show
increases of between 1 and 2 times the endogenous mouse
levels when standardized to porin and levels of 0.7 to 2.2 times
when standardized to actin (Figs. 2B–2D). These data suggest
an increased amount of frataxin within the mitochondria of the
cerebrum and brain stem of both mice, with an approximately
normal number of mitochondria in YG22, but a decrease in
YG8. The fluctuating decreased or increased levels of frataxin
protein that we determined in different rescue mouse tissues
contrasts with our finding of constant decreased frataxin mRNA
levels in all rescue mouse tissues. This discrepancy may be
explained by tissue-dependent variations in posttranscriptional
and posttranslational effects on transgenic frataxin protein
production.
To investigate potential antioxidant changes, comparative
levels of the antioxidant enzymes, CuZnSOD and MnSOD,
were also determined from the same tissue lysates (Figs. 2B, 2E,
and 2F). CuZnSOD showed increases of up to 166% in
cerebrum, brain stem, cerebellum, and heart of both YG22 andYG8 rescue mice compared with wild-type controls and nor-
malized with actin, although changes were not to a significant
level. However, a significant decrease in CuZnSOD was de-
tected in the skeletal muscle of both YG22 and YG8 rescue
mice (40 and 22%, respectively, p<0.01 for each). MnSOD
showed increases of up to 146% in all tissues (with the
exception of YG8 skeletal muscle, which was decreased to
80%) compared with wild-type controls and normalized with
porin, although changes were not to a significant level.
Neurobehavioral deficits
The coordination ability of the YG22 and YG8 rescue mice
was shown to be impaired from the age of 3 months as
determined by reduced performance on an accelerating rotarod
treadmill compared with wild-type littermate controls (p<0.01)
(Fig. 3A). However, the degree of impairment did not extend to
overt ataxia in either line of mice up to the age of 2 years.
Muscle strength, assessed by a forelimb grip strength test, was
decreased in YG22 rescues from 9 months of age (p<0.01), but
no significant changes were detected in the YG8 rescues (Fig.
3B). Locomotor activity, assessed by examining the unrestricted
movement of mice in an open field, was decreased in both lines.
The YG22 rescues showed a decreased trend in locomotor
activity from 6 months of age, but no statistically significant
difference was seen until 1 year (p<0.05). YG8 rescues, on the
other hand, showed a significant decrease in locomotor activity
from 6 months of age (p<0.05) (Fig. 3C). Both YG22 and YG8
lines demonstrated an increase in weight, with statistically
significant differences detected in YG22 rescues from 6 months
Fig. 2. Frataxin and antioxidant enzyme expression levels in YG22 and YG8 rescue mice. (A) Western blot showing comparative levels of frataxin relative to actin in
skeletal muscle samples from human (H), wild-type mouse (M), and YG22 transgenic mouse (TG). (B) Western blot of YG22 and YG8 rescue mouse tissue lysates
(lanes 1, cerebrum; 2, brain stem; 3, cerebellum; 4, heart; 5, skeletal muscle) hybridized with antibodies against frataxin, actin, porin, MnSOD, and CuZnSOD. The
very low levels of YG8 skeletal muscle frataxin, which appear to be negative in this image, were revealed upon longer exposure. (C, D) Levels of transgenic human
frataxin expression as a percentage value of endogenous wild-type mouse frataxin expression, (C) relative to porin controls or (D) relative to actin controls (n=5–8).
Tissues 1–5 are as described for (B). (E) Levels of CuZnSOD in rescue mice as a percentage value of wild-type mouse expression, normalized to actin (n=3–7).
Tissues 1–5 are as described for (B). (F) Levels of MnSOD in rescue mice as a percentage value of wild-type mouse expression, normalized to porin (n=3–6). Tissues
1–5 are as described for (B). Error bars indicate SEM. *p<0.05, **p<0.01.
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(p<0.01) (Fig. 3D). One reason for the observed gain in weights
may be the decreased locomotor activity identified in the mice.
Electrophysiological analysis
Motor and sensory nerve conduction studies were performed
on the sciatic and caudal nerves of 9- to 14-month-old YG22
rescue and wild-type control mice and 20-month-old YG8
rescue and wild-type control mice. Decreases in both the
sensory action potential and the sensory conduction velocity of
the older YG8 rescue mice were detected (Fig. 4), although not
to statistical significance. However, no sensory nerve conduc-tion changes were detected in the younger YG22 rescues, and
no motor nerve conduction changes were detected in either line
of mice (data not shown). Taken together, these findings suggest
a mild, progressive peripheral sensory neuropathy, which is
consistent with an FRDA phenotype.
Histological abnormalities in the dorsal root ganglia (DRG)
and heart
To detect possible neuronal histopathology in the YG22 and
YG8 rescue mice, we examined sections of brain, spinal cord,
and DRG from eight YG22 rescues, six YG8 rescues, and three
wild-type mice. By performing H&E staining and anti-calbindin
Fig. 3. Functional studies of 3-, 6-, 9-, and 12-month-old YG22 and YG8 rescue mice, compared with wild-type controls. (A) Rotarod analysis of YG22 and YG8
rescue mice compared with wild-type littermate controls shows a coordination deficit in both rescue mice from 3 months of age (n=10 and 9, respectively). However, a
direct comparison between YG22 and YG8 experiments is not possible due to the use of different rotarod acceleration rate settings carried out at different periods of
time. (B) Grip strength analysis shows a weakness in YG22 rescues only from 9 months of age (n=6–10). (C) Locomotor analysis identifies a progressive decrease in
the mobility of both rescue mice (n=6–8 and 7–13, respectively). (D) Weight increases are detected in both rescue mice (n=6–16). Error bars indicate SEM. *p<0.05,
**p<0.01.
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Fig. 4. Sensory nerve conduction studies of 20-month-old YG8 rescue mice and
wild-type controls showing a decrease in sensory conduction velocity (SCV)
and sensory action potential (SAP), although not to significance (n=2).
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Purkinje cell abnormalities or granule cell losses that have
previously been reported for frataxin conditional knockout mice
[20]. Neither did we detect any abnormalities in the brain or
spinal cord regions of either line of mice. However, we did
identify pathological changes in the DRG. Prominent giant
vacuoles were identified in the large sensory neuronal cell
bodies of the DRG in both YG8 and YG22 rescue mice but not
in wild-type controls (Fig. 5A). The vacuoles are round, single
or multiple, and appear to be empty. We also detected peripheral
margination of the nucleus in many large neuronal cell bodies,
with or without vacuoles, suggestive of the process of central
chromatolysis. These findings indicate specific degeneration of
cells that also are a primary site of pathology in FRDA patients.
Interestingly, the occurrence of DRG vacuoles shows a
progressive position-dependent profile, which is similar in
both lines of mice. Between the ages of 6 months to 1 year,
vacuoles are detected only in the DRG of the lumbar region, but
after 1 year of age, vacuoles also become apparent within DRG
of the cervical region. Approximately 60% of the lumbar DRG
sections from YG22 rescues and 70% of the lumbar DRG
sections from YG8 rescues have cells containing vacuoles, with
one to seven cells affected in each DRG section. In contrast,
only 16% of the cervical DRG sections have vacuoles, and theFig. 5. Neuronal and cardiac histopathology. (A) H&E-stained section of lumbar DR
neurons containing large vacuoles. Original magnification 400×. (B) Perl's staining
showing characteristic blue staining indicating iron deposition. Original magnificativacuoles are detected in only one cell per DRG section. This
profile resembles the distal-to-proximal “dying-back” phenom-
enon of neurodegeneration that is observed in FRDA patients.
To determine potential hypertrophic cardiomyopathy, the
heart weight/body weight ratio was determined and the heart
examined for histopathology by H&E, trichrome Masson, and
Perl's staining. No increase in heart weight to body weight ratio
was identified and no myofibril disarray or fibrosis was
observed to suggest cardiomyopathy (data not shown). How-
ever, Perl's staining identified iron deposition within the heart,
but only from the oldest (14–18 months) YG22 rescue mice
studied (Fig. 5B). In these cases, Perl's staining of the
cardiomyocytes was prominent but sparse, consistent with
similar findings in FRDA patients.
Ultrastructure pathology
Ultrastructure examination of lumbar DRG from 20-month-
old YG8 rescue mice by electron microscopy confirmed the
presence of large vacuoles within the large neuronal cell bodies
(Fig. 6A), as previously detected by light microscopy.
Chromatolysis was also confirmed by the finding of dispersion
of the rough endoplasmic reticulum ribosomes, leaving regions
of the cell devoid of any cytoplasmic organelles (Fig. 6B).
Lipofuscin deposition, which represents a lysosomal protein
polymer arising from iron-catalyzed oxidation, was pronounced
in DRG neurons (Fig. 6C). Other changes within the lumbar
DRG included the finding of swelling and secondary demye-
lination of large axons (Figs. 6D and 6E). These pathological
changes are all in keeping with oxidative stress and mitochon-
drial dysfunction of degenerating large DRG neurons, which are
then attempting to regenerate by activation of protein synthesis.
Ultrastructure examination of the heart identified patches of
lipofuscin deposition and lysosomes, together with an accumu-
lation of dispersed free glycogen, disrupting the regular arrays
of mitochondria within the cardiomyocytes (Fig. 6F). Lipofus-
cin deposition is a recognized feature within FRDA cardio-
myocytes and dispersed free glycogen accumulation leading to
myofibril distortion has been found in other forms of
hypertrophic cardiomyopathy [25].G from a representative YG22 rescue mouse over 1 year of age, showing two
of a heart section from a representative YG22 rescue mouse over 1 year of age,
on 600×.
Fig. 6. (A–E) Electron micrographs of lumbar DRG from 20-month-old YG8 rescue mice showing examples of: (A) giant vacuoles, (B) chromatolysis, and (C)
lipofuscin deposits within the large neuronal cell bodies. Also detected within the lumbar DRG are instances of: (D) complete demyelination of a large axon with its
associated Schwann cell and (E) large axonal swelling with reduced myelination. (F) Electron micrograph of cardiac muscle from a 20-month-old YG8 rescue mouse
showing lipofuscin deposition and lysosomes disrupting an ordered array of mitochondria. Scale bars represent 10 μm.
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chain function
Previous studies of FRDA patient and mouse model tissues
have demonstrated impaired activity of the iron–sulfur cluster
(ISC)-containing aconitase enzyme and mitochondrial respira-
tory chain (MRC) complexes I, II, and III, but not the non-ISC-
containing MRC complex IV [18,26]. Examination of heart
tissue samples from 6-month-old YG8 rescue mice detected a
decrease in aconitase activity to approximately 66% of wild-
type mouse levels (p<0.05) (Fig. 7). Decreases in MRC
complex I and II/III activity were also detected (79 and 75% of
controls, respectively), although not to significant levels. In
contrast, isolated MRC complex II and MRC complex IV
activities showed no change. These data are in general
agreement with the previous reports of FRDA patient and
mouse model samples. However, the isolated MRC complex IIFig. 7. Mitochondrial respiratory chain and aconitase activities in heart tissue from 6
aconitase (Acon) and citrate synthase (CS). CS activities were divided by 10 (n=6). (B
citrate synthase; MRC I, NADH coenzyme Q1 reductase (NQ1R); MRC II/III, succin
(SQ2R); and MRC IV, cytochrome oxidase (COX). COX/CS ratio was multiplied bactivity was not decreased in the YG8 rescue mice, as has
previously been described in conditional knockout mouse
models [18,20]. Therefore, it is possible that the level of frataxin
reduction in these samples is only just sufficient to induce
changes in the most sensitive enzyme, aconitase. The impaired
aconitase activity may be due to either reduced ISC formation or
oxidative damage.
Oxidative stress
To detect potential oxidative stress in our FRDA models, we
determined the levels of oxidized proteins and malondialdehyde
(MDA; a marker of lipoperoxides) in YG22 and YG8 rescue
mouse cerebrum, cerebellum, heart, and skeletal muscle tissues
compared with wild-type controls. Oxidized proteins were
increased in all samples from both YG22 and YG8 rescue mice
(Fig. 8A). The most prominent significant increases were-month-old YG8 rescue mutant and control mice. (A) The specific activities of
) The mitochondrial respiratory chain (MRC) activities expressed as a ratio with
ate cytochrome c reductase (SCcR); MRC II, succinate coenzyme Q2 reductase
y a factor of 10 (n=4). Activities are expressed as means±SEM. *p=0.03.
Fig. 8. Oxidative stress. (A) Oxyblot analysis detects protein oxidation in
cerebrum, cerebellum, heart, and skeletal muscle tissues of 6- to 9-month old
YG22 and YG8 rescue mice, compared with wild-type controls, measured in
arbitrary units (a.u.) of densitometry (n=8–12). Error bars indicate SEM.
*p<0.05, **p<0.01. (B) TBARS analysis shows levels of MDA (nmol/mg of
protein) as a marker of lipoperoxidation in YG22 cerebrum and heart tissue
compared with wild-type controls (n=6). Error bars indicate SEM. *p<0.05.
587S. Al-Mahdawi et al. / Genomics 88 (2006) 580–590detected in the cerebrum and cerebellum of both lines (p<0.01),
with lesser, but still significant, increases also detected in the
heart and skeletal muscle of both YG8 (p<0.01) and YG22
(p<0.05) mice. The finding of increased oxidized proteins in
the YG22 cerebrum is somewhat at odds with our previous
finding of an increased level of frataxin protein in this tissue,
suggesting reduced functional efficiency of the transgenic
human frataxin protein. Increased lipid peroxidation, as
determined by MDA levels, was also detected in cerebrum
and heart samples from YG22 rescue mice, but only the heart
showed a statistically significant increase (p<0.05) (Fig. 8B).
Discussion
Although the exact mechanisms that cause FRDA are still
under investigation, several specific features of FRDA
molecular pathology are now well established. Thus, the
majority of FRDA patients are homozygous for GAA repeat
expansion mutations within intron 1 of the FXN gene, leading to
decreased levels of frataxin, subsequent oxidative stress, iron
deposition, and ultimately neurodegeneration, primarily in the
large sensory neurons of the DRG, and hypertrophic cardio-myopathy. We have been able to recapitulate many such
features of FRDA disease in the mouse by establishing two lines
of model mice that express frataxin only from GAA repeat
expansion-containing FXN transgenes.
We have previously shown that the GAA repeat somatic
instability pattern in our YG22 and YG8 transgenic mice
closely resembles the GAA repeat dynamics in FRDA patients
[24]. Our initial interpretation of the Western blot data from this
study, which showed a more intense signal from the human
frataxin compared to the mouse frataxin, led us to speculate on
likely overexpression of human frataxin in YG22 or YG8
knockout rescue mice [24]. However, we have now demon-
strated that both YG22 and YG8 rescue mice express
comparatively decreased levels of human frataxin mRNA in
all tissues and decreased levels of human frataxin protein in at
least some tissues compared with endogenous mouse levels.
Overall the YG8 rescue mice demonstrate slightly less frataxin
mRNA and protein expression, combined with marginally
higher amounts of protein oxidation, compared with the YG22
mice. Therefore, it is possible that the additional 90 GAA
repeats in the YG8 line are responsible for producing a slightly
more severe phenotype. Previous GAA expansion mutation
knock-in studies have shown that mice expressing 25–36%
endogenous mouse frataxin levels do not show an obvious
pathological phenotype [22], although a clear microarray gene
expression phenotype has been determined [27]. These mouse
frataxin levels are similar to the human frataxin levels that we
have determined in our heart samples. However, due to its
slightly different amino acid composition, human frataxin may
not function at 100% of endogenous mouse frataxin efficiency.
Therefore, the levels of frataxin that we see here (67 and 42% in
cerebellum, 37 and 25% in heart, and 10 and 9% in skeletal
muscle of YG22 and YG8 rescue mice, respectively) may in
fact represent an even more “functional” decrease, resulting in
the pathological phenotype that we describe.
Age-related somatic increases in GAA repeats have pre-
viously been detected in the cerebrum, brain stem, and
cerebellum of both YG22 and YG8 transgenic mice, but no
such increases were detected in the heart or skeletal muscle [24].
Therefore, the pattern of frataxin expression in our YG22 and
YG8 rescue mice (highest in cerebrum and brain stem, lowest in
skeletal muscle) is not likely to be entirely due to somatic
increases in GAA repeat expansions. A similar pattern of “high
brain and low skeletal muscle” frataxin expression has been
reported in lines of human FXN BAC transgenic mice that
contain normal-sized GAA repeats [28]. Thus, unknown tissue-
specific regulatory factors would appear to be acting on human
FXN transgenes within the context of the mouse. As yet there
are insufficient data available on human tissue samples to
determine if a similar differential pattern of frataxin expression
is present in FRDA and thus how representative our mouse
models are in this regard.
That being said, the differentially reduced levels of frataxin
in our mouse models are sufficient to induce a mild FRDA-like
pathological phenotype. Impaired aconitase activity, oxidative
stress, and functional deficits are apparent, although not severe,
and neuronal histopathology and iron deposition within the
588 S. Al-Mahdawi et al. / Genomics 88 (2006) 580–590heart are later progressive effects. This phenotype is indicative
of the early effects of FRDA pathology that precede overt ataxia
and the later development of hypertrophic cardiomyopathy.
Indeed, these mild mouse models can be considered represen-
tative of the less severe, later onset cases of FRDA. The 190 and
190+90 GAA repeat expansion mutation sizes within our
mouse models are also in keeping with the cases of later onset
FRDA that have smaller GAA allele sizes of fewer than 200
repeats [29–33].
The vacuoles identified in the DRG of our mouse models
appear similar to those in the “Cb” neuron-specific frataxin
conditional knockout model reported by Simon et al. [20].
However, an additional finding within our models is the
progression of vacuolar pathology from affected distal lumbar
regions at only 6 months of age to more proximal cervical
regions at 13–15 months. This resembles the dying-back
phenomenon of neurodegeneration that is observed in FRDA
patients. Although, to our knowledge, DRG vacuoles have not
been described in FRDA patients, loss of large sensory DRG
cell bodies is a hallmark of the disease. Thus, it is likely that we
are identifying a milder or earlier effect in our mouse models,
before the DRG neurons degenerate and are lost completely.
The identification of lipofuscin deposition, chromatolysis, and
swelling and demyelination of axons in the DRG can be
explained by cells that are suffering from chronic oxidative
damage. In this sense, our FRDA mouse models are similar to
the mouse model of ataxia with vitamin E deficiency, which
shows lipofuscin deposition in DRG of mice over 1 year of age,
indicating chronic oxidative stress [34]. Although frataxin
conditional knockout mouse models have reproduced many
other features of FRDA pathology, there is currently some
debate concerning oxidative stress status. Studies of neuronal
and cardiac conditional knockout models indicate no, or
insignificant, oxidative stress [35,36], whereas pancreatic and
hepatic conditional knockout models demonstrate distinct
oxidative stress [19,21]. Our own models demonstrate an
obvious, but not severe, degree of oxidative stress. This may be
due to the fact that our models have residual frataxin in all
tissues, which may also be the case with the pancreatic and
hepatic knockout models, but not the neuronal and cardiac
knockout models, which have complete frataxin loss in specific
tissues. Our mice also have a mitochondrial respiratory chain
that shows only a slight overall functional deficit and,
therefore, continues to produce damaging free radicals. The
greater loss of aconitase activity than MRC complex activity
deficits suggests that aconitase impairment is a prominent early
feature, even in mild cases of FRDA. The increases that we
found in CuZnSOD and MnSOD are generally consistent with
a reaction to oxidative stress in our FRDA mouse model
tissues. However, where there is the greatest decrease in
frataxin (i.e., skeletal muscle) we actually see a decrease in
both CuZnSOD and MnSOD. This indicates a different
susceptibility or handling of this tissue to mild oxidative
stress. The identification of iron deposition in the hearts of only
our older mice confirms the later onset aspect of this pathology,
as previously described for cardiac frataxin conditional
knockout mouse mutants [18].Understanding that FRDA is caused by an unstable GAA
repeat sequence, leading to decreased levels of frataxin, has
given rise to novel ideas for frataxin-increasing therapies. We
believe that we have generated a GAA-repeat-based mouse
model of FRDA that would be suitable for the investigation of
many different therapeutic strategies. These include the possible
use of iron chelators and antioxidants, targeted preferentially to
the mitochondria [37,38], as well as novel drugs aimed at up-
regulation of frataxin expression, such as hemin, butyric acid,
and cisplatin [39,40]. However, the fact that our FRDA mouse
models have been generated by the introduction of a GAA
repeat expansion mutation also makes them amenable to novel
therapeutic strategies aimed at interacting with and modifying
the GAA repeat expansion itself.
Materials and methods
Production and genotyping of genetically modified mice
GAA repeat expansion-containing YG8 and YG22 transgenic mice [24]
were first crossed with heterozygous Fxn knockout mice [17] to produce mice
containing both the transgene and the knockout allele. A second cross with
heterozygous Fxn knockout mice then produced viable FRDA model mice
containing the human FXN transgene on an Fxn null background. Genotyping
of GAA repeats and Fxn allele status was performed as previously described
[24].
mRNA and protein expression analysis
mRNA was isolated and RT-PCR amplified for 25 cycles using human/
mouse frataxin exon 3/4 primers FRT1 and RRTII, followed by digestion with
mouse-specific BstXI and human-specific AflIII restriction enzymes as
previously described [23]. Mouse Hprt RT-PCR was also carried out for 25
cycles using the primers and conditions described by Puccio et al. [18]. DNA
products were resolved in 3% agarose gels and UV images were analyzed by
UN-SCAN-IT (Silk Scientific Corp.) densitometry.
Frataxin Western blot analysis was carried out using a recombinant anti-
mature frataxin antibody (G. Isaya, Mayo Clinic) as previously described [23].
Other immunodetection was carried on the same Western blots using antibodies
against actin (Sigma), porin (Cambridge Bioscience), MnSOD (Abcam), and
CuZnSOD (Abcam). Densitometry was carried out using UN-SCAN-IT
software (Silk Scientific Corp.).
Functional studies
Rotarod analysis was performed using a Ugo-Basille 7650 accelerating
rotarod treadmill apparatus. Mutant and control littermate mice ages 3, 6, 9, and
12 months (n=5–10) were placed on the rod and four trials were performed with
the speed of the rotation gradually increasing from 4 to 40 rpm over a period of
approximately 3–5 min. A period of 10 min rest was given between each trial.
The time taken for each mouse to fall from the rod was recorded. Grip strength
was assessed by holding mice by the base of the tail, while their forepaws
gripped onto a horizontal bar that was attached to a tension spring. The mice
were gently pulled backward until they let go of the bar and the distance pulled
in millimeters was recorded. Locomotor activity was assessed by placing the
mice in a gridded open-field Perspex box and the number of gridded squares
entered by the mouse over a period of 20 s was recorded.
Electrophysiology
Electrophysiological recordings were carried out on anesthetized 20-month-
old YG8 rescue mice, 9- to 14-month-old YG22 rescue mice, and wild-type
controls. Motor nerve conduction was investigated by placing electrodes in the
hind-paw muscle and stimulating the sciatic nerve. Measurements of amplitude,
589S. Al-Mahdawi et al. / Genomics 88 (2006) 580–590distal latency, and proximal latency were taken, and the motor conduction
velocity was then determined. Sensory nerve conduction was investigated by
placing electrodes at two positions in the tail skin and stimulating the caudal
nerve. Measurements of the sensory action potential were taken, and the sensory
conduction velocity was then determined.
Histology
For histological preparations, terminally anesthetized mice were fixed by
intracardial perfusion with 4% paraformaldehyde in phosphate-buffered saline
(PBS). The fixed mouse tissues were dissected, embedded in paraffin wax, and
sectioned by standard methods. Sections were deparaffinized with Histoclear
(National Diagnostics) and slides were stained with hematoxylin and eosin or
trichrome Masson stains. Perl's technique was used to detect ferric iron as
previously described [17].
Electron microscopy
Mice of 20 months of age were perfused via a cannula in the heart with 1%
glutaraldehyde and 1% paraformaldehyde plus 1% dextran, all in 0.1 M PIPES
buffer. Tissues were dissected out, fixed for several hours in the same solution,
and then postfixed overnight in 1% osmium tetroxide +1.5% potassium
ferricyanide and 3% sodium iodate. Tissues were then dehydrated through
increasing concentrations of ethanol and embedded in Durcupan via 1,2-epoxy
propane. Thin sections for light microscopy were stained with thionin and
acridine orange and ultrathin sections for electron microscopy were contrasted
with uranyl acetate and lead citrate.
Biochemical measurements
Dissected mouse heart tissues were snap-frozen in liquid nitrogen.
Mitochondrial respiratory chain and aconitase activities were determined as
previously described [26].
Oxidative stress
Protein lysates were prepared according to Campuzano et al. [3]. For each
assay, 10 μg of protein was used and the concentration was determined by using
the BCA Protein Assay Reagent Kit (Pierce). Proteins were then modified by the
use of the OxyBlot Protein Oxidation Detection Kit (Chemicon International).
Duplicate samples were used for each assay and controls of unmodified samples
were also included. After the assay was performed according to the
manufacturer's instructions, each sample was diluted to 100 μl in 1× Laemmli
buffer [41], with 2-mercaptoethanol and no added glycerol. Samples were then
applied to a slot-blot apparatus and washed with the same buffer, followed by
electroblot transfer buffer. The filters were air-dried and treated with the
antibody provided in the kit and subsequently visualized on X-OMAT X-ray
film. Densitometry was performed using UN-SCAN-IT software (Silk Scientific
Corp.) and the final values were calculated as ratios to the protein concentration
used per assay.
TBARS (thiobarbituric acid-reactive substances) assay for MDA
Using a modification of the method described by Ledwozyw et al. [42], brain
and heart tissues from wild-type and mutant mice were homogenized to 20%
(w/v) in Dulbecco's PBS. Samples were then centrifuged at 2000g for 10 min
and supernatants were collected. Each supernatant (0.1 ml) was mixed with
20% (w/v) trichloroacetic acid in 0.6 M HCl and left at room temperature for
15 min. This was then mixed with thiobarbituric acid (TBA; prepared by
dissolving 0.5 g of TBA in 6 ml of 1 M NaOH and then adding 69 ml of water).
The mixture was then heated to 100°C for 30 min, cooled to room temperature
for 10 min, and then extracted with 0.8 ml of n-butanol. Samples were vortexed
and then centrifuged at 1500g for 10 min. The upper organic phase was
collected and the absorbance of each sample was determined at 532 nm vs
n-butanol. The concentration of MDA (which forms an adduct with TBA) was
determined from a standard curve, obtained from using different concentrations
of MDA (Aldrich). The protein concentration of each tissue homogenatesupernatant was determined by the BCA Protein Assay (Pierce) and the final
value of MDA in each tissue was presented as nmol/mg of protein used.
Statistical analysis
Mendelian ratios were determined using χ2 analysis, rotarod analysis was
carried out using ANOVA with repeated measures, and all other functional,
mRNA, Western blot, oxyblot, TBARS, and enzyme activities were analyzed
using the Student t test.
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